The ClockMatrix family is comprised of three lines of devices:
- System Synchronizers, which generate telecom-compliant clocks for network equipment
- Port Synchronizers, for extending telecom-compliant clocks to the many ports in network equipment
- Universal Frequency Translators (UFT), which perform jitter attenuation, clock generation and frequency translation functions for general purpose applications.
“We recognized several years ago that the wireless carriers’ impending migration to 5G networks would require more precise time synchronization, and so we designed our ClockMatrix family to both upgrade the time precision of existing network equipment as well as support new equipment designs to enable a smooth migration,” said Kris Rausch, vice president and general manager of IDT’s Timing Products Division. “ClockMatrix devices are the only timing solutions on the market to combine such performance and features with exceptional flexibility, which not only makes them excellent for 5G networking equipment, but a variety of other applications.”
The ClockMatrix devices’ combination of features and performance make them ideal for a variety of network devices used in both backhaul and fronthaul 5G applications. For example, they can make extremely accurate phase measurements on timing signals using their multiple inputs and precision time-to-digital converters (TDC), with some family members capable of measuring to less than 1 ps. Additionally, they offer precise control of input-to-output phase (as low as 1ps steps) along with excellent close-in phase noise performance.
The pulse width modulation (PWM) capability of the devices eliminates the need for customers to redesign existing backplanes. This allows manufacturers to get new line cards to market quickly and to target an existing installed base with a simple migration path. PWM can transmit and receive clocks, frames pulses and time-of-day (TOD) data in one signal.
The ClockMatrix family of synchronizers meet carriers’ constant time error (cTE) and G.8273.2 telecom boundary clock (T-BC) requirements. Their exceptional phase alignment performance makes the devices ideal for T-BC classes C and D, with demonstrated cTE performance better than 5 nanoseconds in customer systems.
More information on the ClockMatrix family, including documentation, samples and evaluation kits, is available at idt.com/clockmatrix.
Integrated Device Technology, Inc. develops system-level solutions that optimize its customers’ applications. IDT’s market-leading products in RF, high performance timing, memory interface, real-time interconnect, optical interconnect, wireless power, and smart sensors are among the company’s broad array of complete mixed-signal solutions for the communications, computing, consumer, automotive and industrial segments. Headquartered in San Jose, Calif., IDT has design, manufacturing, sales facilities and distribution partners throughout the world. IDT stock is traded on the NASDAQ Global Select Stock Market® under the symbol “IDTI.” Additional information about IDT can be found at idt.com. Follow IDT on Facebook, LinkedIn, Twitter, and YouTube.
© 2019, Integrated Device Technology, Inc. IDT and the IDT logo are trademarks or registered trademarks of Integrated Device Technology, Inc., and its worldwide subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.
Director, Demand Creation & Communications
Phone: (408) 574-6640
SOURCE Integrated Device Technology, Inc.
First Reported Allogeneic CAR T Data in Multiple Myeloma Highlights Initial Safety and Efficacy in Heavily Pretreated, Refractory PatientsIn the Ongoing Study, 31 Patients Were
– Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion –– Sickle cell disease: All three
– Evidence of biologic activity observed in each dose-escalation cohort treated to date –– Clinical activity includes one CR in a patient with a NPM1
Lead immuno-oncology development candidate NTLA-5001 shows high anti-tumor activity as promising cancer treatment in proof-of-concept mouse models of acute leukemiasProprietary process enhances tumor control in
Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathiesIND filing for EDIT-301 planned by end of 2020CAMBRIDGE,
CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically